Article, News
FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its PTX-100 drug by the US Food and Drug Administration (FDA)….
Article, News
Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL)….
Article, News
Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s…
Article, News
Prescient Therapeutics receives FDA orphan drug status for PTX-100 to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead candidate PTX-100…
Article, News
Prescient Therapeutics (ASX:PTX) reports progress in cancer studies during H1 FY23 – Kalkine Media
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) — focused on the development of novel and personalised cancer-related therapies — has released its half-year report for…
Article, News
PTX-100 shows encouraging efficacy signals and safety in area of high unmet clinical need
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage assets across CAR-T and targeted cell therapies. The company has…
Article, News
Breakthrough cancer therapies develop while traditional treatments remain prevalent
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy and radiation. Each poses their own benefits, risks and limitations….
Article, News
Prescient (ASX:PTX) ends last quarter on firm financial footing and key clinical developments – Kalkine Media
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving player for the next generation of personalised therapies for cancer.
Article, News
Topped up with cash, Prescient presses on in US$280 billion industry
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by the World Health Organisation, but in the same year nearly…
News
2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. …